Repligen (RGEN) Stock Forecast & Price Target

Compare

959 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGEN Analyst Ratings

Strong Buy

10 Buy

3 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGEN Stock 12 Month Forecast

Average Price Target

$177.17

▲(48.07% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $177.17 with a high forecast of $220.00 and a low forecast of $126.00. The average price target represents a 48.07% change from the last price of $119.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"117":"$117","143":"$143","169":"$169","195":"$195","221":"$221"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$220.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":177.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$177.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":126,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$126.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[117,143,169,195,221],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.91,126.68615384615384,134.4623076923077,142.23846153846154,150.01461538461538,157.79076923076923,165.56692307692308,173.34307692307692,181.11923076923077,188.89538461538461,196.67153846153846,204.4476923076923,212.22384615384615,{"y":220,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.91,123.39153846153846,127.87307692307692,132.35461538461539,136.83615384615385,141.3176923076923,145.79923076923077,150.28076923076924,154.76230769230767,159.24384615384616,163.7253846153846,168.20692307692306,172.68846153846152,{"y":177.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.91,119.45538461538462,120.00076923076922,120.54615384615384,121.09153846153846,121.63692307692307,122.18230769230769,122.72769230769231,123.27307692307693,123.81846153846153,124.36384615384615,124.90923076923077,125.45461538461538,{"y":126,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":165.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.93,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.94,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$220.00

Average Price Target$177.17

Lowest Price Target$126.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jack Scalprey

TR | OpenAI - 4o

$126

Hold

5.31%

Upside

Reiterated

08/21/25

AI Generated ArticleAI Generated Article

Brandon Couillard

Wells Fargo

$180→$175

Buy

46.26%

Upside

Reiterated

07/30/25

Wells Fargo Sticks to Their Buy Rating for Repligen (RGEN)Wells Fargo analyst Brandon Couillard lowered the price target on Repligen (NASDAQ: RGEN) to $175.00 (from $180.00) while maintaining a Overweight rating.

Paul Knight

KeyBanc

$220

Buy

83.87%

Upside

Reiterated

07/30/25

Analysts Are Bullish on Top Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Repligen (RGEN)

Daniel Markowitz CFA

Evercore ISI

$130

Hold

8.65%

Upside

Reiterated

07/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)

Matt Hewitt

Craig-Hallum

$204

Buy

70.50%

Upside

Reiterated

07/30/25

Craig-Hallum Keeps Their Buy Rating on Repligen (RGEN)

Daniel Arias

Stifel Nicolaus

$207

Buy

73.00%

Upside

Reiterated

07/30/25

Stifel Nicolaus Sticks to Its Buy Rating for Repligen (RGEN)

Puneet Souda

Leerink Partners

$200

Buy

67.15%

Upside

Reiterated

07/30/25

Repligen's Strong Market Position and Growth Prospects Justify Buy Rating

Conor McNamara

RBC Capital

$193→$204

Buy

70.50%

Upside

Reiterated

07/30/25

RBC Capital Keeps Their Buy Rating on Repligen (RGEN)RBC Capital analyst Conor McNamara raised the price target on Repligen (NASDAQ: RGEN) to $204.00 (from $193.00) while maintaining a Outperform rating.

Luke Sergott

Barclays

$150

Buy

25.37%

Upside

Reiterated

07/30/25

Repligen (RGEN) Receives a Buy from Barclays

Brendan Smith

TD Cowen

$200

Buy

67.15%

Upside

Reiterated

07/29/25

Repligen's Strong Organic Growth and Strategic Positioning Make it a Compelling Buy

Matt Larew

William Blair

―

Buy

―

Reiterated

07/29/25

Repligen's Strong Q2 Performance and Growth Prospects Justify Buy RatingWe will update our model and estimates after the conference call. What Happened Repligen’s second-quarter results came in ahead on the top line and the company raised the low end of its non-COVID organic growth guidance. Revenue: $182.4 million beat our $177.1 million estimate and consensus of $175.2 million (non-COVID organic growth was 17% versus our roughly 14% estimate). Gross margin: 51.1% (WB: 52.0%; $32.2 million (WB: $33.7 million; Street: $32.1 million). Adjusted EPS: $0.37 (WB: $0.41; Updated full-year guidance calls for revenue of $715 million to $735 million (up from $695 million to $720 million), non- COVID organic growth of 12.5% to 15.5% (up from 11.5% to 15.5%), adjusted EBITDA margin of 19.5% to 20.5% (unchanged), and adjusted EPS of $1.65 to $1.75 (up from $1.63 to $1.72).

Kyle Mikson CFA

Canaccord Genuity

$150

Hold

25.37%

Upside

Reiterated

07/29/25

Repligen (RGEN) Gets a Hold from Canaccord Genuity

Steven Etoch

Stephens

$160

Buy

33.72%

Upside

Initiated

07/21/25

Repligen resumed with an Overweight at StephensRepligen resumed with an Overweight at Stephens

Ram Selvaraju

H.C. Wainwright

$180

Buy

50.44%

Upside

Reiterated

05/05/25

Repligen's Strategic Growth and Resilience Drive Buy Rating with $180 Price Target

Robert Wasserman

Benchmark Co.

―

Hold

―

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jack Scalprey

TR | OpenAI - 4o

$126

Hold

5.31%

Upside

Reiterated

08/21/25

AI Generated ArticleAI Generated Article

Brandon Couillard

Wells Fargo

$180→$175

Buy

46.26%

Upside

Reiterated

07/30/25

Paul Knight

KeyBanc

$220

Buy

83.87%

Upside

Reiterated

07/30/25

Analysts Are Bullish on Top Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Repligen (RGEN)

Daniel Markowitz CFA

Evercore ISI

$130

Hold

8.65%

Upside

Reiterated

07/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Ionis Pharmaceuticals (NASDAQ: IONS) and Repligen (NASDAQ: RGEN)

Matt Hewitt

Craig-Hallum

$204

Buy

70.50%

Upside

Reiterated

07/30/25

Craig-Hallum Keeps Their Buy Rating on Repligen (RGEN)

Daniel Arias

Stifel Nicolaus

$207

Buy

73.00%

Upside

Reiterated

07/30/25

Stifel Nicolaus Sticks to Its Buy Rating for Repligen (RGEN)

Puneet Souda

Leerink Partners

$200

Buy

67.15%

Upside

Reiterated

07/30/25

Repligen's Strong Market Position and Growth Prospects Justify Buy Rating

Conor McNamara

RBC Capital

$193→$204

Buy

70.50%

Upside

Reiterated

07/30/25

Luke Sergott

Barclays

$150

Buy

25.37%

Upside

Reiterated

07/30/25

Repligen (RGEN) Receives a Buy from Barclays

Brendan Smith

TD Cowen

$200

Buy

67.15%

Upside

Reiterated

07/29/25

Repligen's Strong Organic Growth and Strategic Positioning Make it a Compelling Buy

Matt Larew

William Blair

―

Buy

―

Reiterated

07/29/25

Kyle Mikson CFA

Canaccord Genuity

$150

Hold

25.37%

Upside

Reiterated

07/29/25

Repligen (RGEN) Gets a Hold from Canaccord Genuity

Steven Etoch

Stephens

$160

Buy

33.72%

Upside

Initiated

07/21/25

Repligen resumed with an Overweight at StephensRepligen resumed with an Overweight at Stephens

Ram Selvaraju

H.C. Wainwright

$180

Buy

50.44%

Upside

Reiterated

05/05/25

Repligen's Strategic Growth and Resilience Drive Buy Rating with $180 Price Target

Robert Wasserman

Benchmark Co.

―

Hold

―

Reiterated

04/30/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), SAGE Therapeutics (NASDAQ: SAGE) and Repligen (NASDAQ: RGEN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

1 Month

xxx

Success Rate

11/19 ratings generated profit

Average Return

+2.29%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.89% of your transactions generating a profit, with an average return of +2.29% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+0.55%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +0.55% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

11/23 ratings generated profit

Average Return

+15.52%

reiterated a buy rating 24 days ago

Copying Daniel Arias's trades and holding each position for 1 Year would result in 47.83% of your transactions generating a profit, with an average return of +15.52% per trade.

2 Years

xxx

Success Rate

7/23 ratings generated profit

Average Return

+18.75%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 30.43% of your transactions generating a profit, with an average return of +18.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGEN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGEN has received 17 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. RGEN average Analyst price target in the past 3 months is 177.17.

Each month's total comprises the sum of three months' worth of ratings.

RGEN Financial Forecast

RGEN Earnings Forecast

Next quarter’s earnings estimate for RGEN is $0.42 with a range of $0.37 to $0.45. The previous quarter’s EPS was $0.37. RGEN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.05% of the time in the same period. In the last calendar year RGEN has Outperformed its overall industry.

RGEN Sales Forecast

Next quarter’s sales forecast for RGEN is $181.43M with a range of $169.95M to $185.70M. The previous quarter’s sales results were $182.37M. RGEN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.25% of the time in the same period. In the last calendar year RGEN has Outperformed its overall industry.

RGEN Stock Forecast FAQ

What is RGEN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen Corp’s 12-month average price target is 177.17.

What is RGEN’s upside potential, based on the analysts’ average price target?

Repligen Corp has 48.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RGEN a Buy, Sell or Hold?

Repligen Corp has a consensus rating of Strong Buy which is based on 10 buy ratings, 3 hold ratings and 0 sell ratings.

What is Repligen Corp’s price target?

The average price target for Repligen Corp is 177.17. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $220.00 ,the lowest forecast is $126.00. The average price target represents 48.07% Increase from the current price of $119.65.

What do analysts say about Repligen Corp?

Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of RGEN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Repligen (RGEN) Stock Forecast & Price Target

RGEN Analyst Ratings

RGEN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGEN Analyst Recommendation Trends

RGEN Financial Forecast

RGEN Earnings Forecast

RGEN Sales Forecast

RGEN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts